Individualized neoantigen therapy could be ‘huge leap’ toward personalized medicine

Source: Healio , August 2024

Key takeaways:

• Treatment induced sustained T-cell responses among patients with melanoma and non-small cell lung cancer.
• Phase 3 trials in both cancer types are open.

A novel therapeutic approach stimulated new and existing T-cell responses among patients with melanoma or non-small cell lung cancer, according to results of a phase 1 trial.

Researchers reported no dose-limiting toxicities and no grade 4 or worse adverse events among participants who received the individualized neoantigen therapy mRNA-4157 (V940) [Moderna/Merck] alone or with pembrolizumab (Keytruda, Merck).
READ THE ORIGINAL FULL ARTICLE